Pharma BD Deal Intelligence
Mylan's 2006 acquisition of ~71.5% of Matrix Laboratories for ~$736M built the API/manufacturing backbone behind its rise to a $5.5B-revenue global generics company by 2010. But chronic FDA quality failures at former Matrix plants and a 2023-24 divestiture back to the founder's family make this a mixed, not clean, win.
Matrix became the backbone of Mylan's global API/manufacturing platform for 15+ years, but chronic FDA quality problems and an eventual 2023-24 divestiture (sold back to the founder's family) mean the long-run outcome is mixed, not a clean win.
Full analysis, sources & comparables →This is an extremely complementary transaction that accomplishes a number of Mylan's key objectives. - Robert J. Coury, Mylan CEO. Matrix's Executive Chairman…
We think the deal Mylan announced today may turn out to be both expensive and problematic for the company. - Banc of America Securities analyst David W. Maris,…
Matrix gave Mylan access to China, India and African markets, and the deal was characterized as the largest-ever takeover in the Indian pharma industry at the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Indian generics/API; up to 71.5% controlling interest at INR 306/share
Matrix became the backbone of Mylan's global API/manufacturing platform for 15+ years, but chronic FDA quality problems and an eventual 2023-24 divestiture (sold back to the founder's family) mean the long-run outcome is mixed, not a clean win.
Assessment window: 15yr post-close.
This is the same Mylan–Matrix transaction at the closing milestone (Aug 28, 2006 step-1 closing of the controlling stake). The deal was an API/manufacturing acquisition rather than a single-indication asset deal; Matrix was the largest global supplier of generic ARV APIs used in HIV/AIDS therapy and a broad-line generic API producer.
By the August 2006 step-1 close, Mylan had secured a controlling 51.5% stake in Matrix and was making an open offer for an additional 20% to reach 71.5%. The competitive context: India's generics/API space at that time was dominated by Ranbaxy, Dr. Reddy's, Cipla, Aurobindo and Wockhardt, while US generics were led by Teva, Sandoz, Mylan, Watson and Barr. By acquiring Matrix, Mylan leapfrogged peers on vertical integration — most US-based generics still bought APIs from third-party Indian suppliers — and locked up the leading global ARV API source for HIV access programs (PEPFAR, Global Fund tenders). The deal was 'moderately accretive' guidance was given for fiscal 2008, the first full year post-close. The Matrix platform later anchored Mylan's emerging-markets strategy, with the eventual 2011 rebrand of Matrix as 'Mylan' in India.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Laboratories Inc. / Matrix Laboratories Limited (this deal) | 2006 | $736M | 66 |
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) | 2007 | $6.7B | 81 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2005 | $736M | 39 |
| Mylan Laboratories Inc. / King Pharmaceuticals Inc. | 2004 | $4.0B | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |